Sensei Biotherapeutics, Inc. (SNSE)

1,0200 -0,0200 (-1,92%) Börsenschluss: 04:00PM EDT

Sensei Biotherapeutics, Inc.

1405 Research Boulevard
Suite 125
Rockville, MD 20850
United States
240 243 8000
https://www.senseibio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 28

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. John K. Celebi M.B.A.	President, CEO & Director	799,69k	N/A	1972
Dr. Edward Van der Horst Ph.D.	Chief Scientific Officer	444,87k	N/A	1973
Ms. Lora Pike	Vice President of Investor Relations & Communications	N/A	N/A	N/A
Mr. Christopher W. Gerry J.D.	Senior VP, General Counsel & Secretary	N/A	N/A	N/A
Ms. Stephanie Krebs M.B.A., M.S.	Chief Business Officer	N/A	N/A	N/A
Dr. Aaron Weitzman FACP, M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Corporate Governance

Sensei Biotherapeutics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 7, Shareholderrechte: 10, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.